Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Soleno Therapeutics (NASDAQ: SLNO) announced that CEO Anish Bhatnagar will present a corporate overview at the H.C.

Rhea-AI Summary

Soleno Therapeutics (NASDAQ: SLNO) announced that CEO Anish Bhatnagar will present a corporate overview at the H.C. Wainwright 24th Global Investment Conference from September 12-14, 2022. The conference will take place virtually and at Lotte New York Palace Hotel. The presentation will be available on-demand starting September 12 at 7:00 a.m. ET. Soleno focuses on developing innovative therapies for rare diseases, with its lead candidate, DCCR, currently in Phase 3 trials for Prader-Willi syndrome.

Argus Session date unavailable

-4.31% session move Open Argus

Details

News Market Reaction – SLNO

The recorded move for SLNO in the trading session of this news was -4.31%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24^th Global Investment Conference, being held September 12-14, 2022, virtually and in-person at the Lotte New York Palace Hotel in New York, NY.

The presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 a.m. Eastern Time on Monday, September 12, 2022, and a copy of the information presented will be posted in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Soleno Therapeutics present at the H.C. Wainwright conference?

Soleno Therapeutics will present at the H.C. Wainwright 24th Global Investment Conference on September 12-14, 2022.

What is the focus of the presentation by Soleno Therapeutics at the conference?

The presentation will provide a corporate overview and detail their developmental progress in rare diseases.

What is DCCR and its significance to Soleno Therapeutics?

DCCR is Soleno's lead candidate, being developed as a once-daily oral tablet for treating Prader-Willi syndrome.

Where can I find the on-demand presentation by Soleno Therapeutics?

The presentation will be available on-demand on the H.C. Wainwright conference portal starting September 12, 2022.

What is the current stage of DCCR in clinical trials?

DCCR is currently being evaluated in an ongoing Phase 3 clinical development program.